Johnson & Johnson is running late-stage clinical trials on a drug called seltorexant, designed to treat depression in people who also struggle with insomnia. The prediction is that the trial will announce positive results — meaning the drug worked better than placebo — by early November 2026, putting the company on track to file for FDA (the US drug regulator) approval. This matters because a drug that tackles both depression and sleep problems at once could help millions of people who don't respond well to standard antidepressants.
Orexin antagonism has cleaner blinding than psychedelics; J&J's data discipline and the active trial signal today suggest a filing-positive readout.
Join our community — a free weekly Zoom circle with a master facilitator. Come sit with us first; the rest reveals itself.
Join the Free Weekly Circle →